Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)

Read full text Summarise with VIRAT
Authors: Yosuke Kito, Kentaro Yamazaki, Hirokazu Shoji, Takeshi Yamada, Takahiro Tsushima, Seiichiro Mitani, Kazuhiro Shiraishi, Hisateru Yasui, Hiroki Hara, Kenro Hirata, Taito Esaki, Yudai Shinohara
+15 more Takao Tsuzuki, Shinya Kajiura, Toshiki Masuishi, Naoki Izawa, Eishi Baba, Kohei Murata, Naoya Akazawa, Yozo Suzuki, Hironaga Satake, Narikazu Boku, Ichinosuke Hyodo, Kenichi Yoshimura, Hisato Kawakami, Shuichi Hironaka, Kei Muro
Cited by: 0
References: 30

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: FOLFOXIRI plus bevacizumab improved efficacies and increased some adverse events in untreated metastatic colorectal cancer (mCRC), compared with the doublet plus bevacizumab. The clinical outcomes of ramucirumab (RAM) in combination with FOLFIRI or FOLFOXIRI as a first-line treatment are unknown. In this randomized phase II study (WJOG9216G), we compared the efficacy and safety of these regimens to determine which is more promising. METHODS: Patients with untreated mCRC were randomly assigned to the FOLFIRI-RAM or FOLFOXIRI-RAM arms. The primary endpoint was a confirmed objective response rate (ORR), and secondary endpoints included early tumor shrinkage (ETS), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: In total, 122 patients were randomized. The confirmed ORR was 59.3% and 60.3% in the FOLFIRI-RAM and FOLFOXIRI-RAM arms, respectively (odds ratio 1.04; P = 0.91). With a median follow-up period of 42.1 and 40.4 months, PFS was comparable between the FOLFIRI-RAM and FOLFOXIRI-RAM arms (median, 11.5 and 10.5 months). ETS rate (71.2% and 52.4%) and OS (median, 32.6 and 28.2 months) were significantly better in the FOLFIRI-RAM arm than in the FOLFOXIRI-RAM arm. The major grade ≥ 3 adverse events in the FOLFIRI-RAM and FOLFOXIRI-RAM arms were neutropenia (44.1% and 72.6%), anorexia (3.4% and 14.5%), and febrile neutropenia (3.4% and 11.3%). CONCLUSIONS: FOLFOXIRI plus RAM was not superior to FOLFIRI plus RAM in terms of efficacy, including ORR, in patients with untreated mCRC. Instead, first-line FOLFIRI plus RAM showed clinical efficacy and safety profiles comparable to those of doublet chemotherapy plus bevacizumab.

Fields of Study & Subjects

Colorectal Cancer Treatments and Studies Colorectal Cancer Surgical Treatments Intraperitoneal and Appendiceal Malignancies

Publication details

Journal / source
European Journal of Cancer
Volume
238
Pages
116688–116688
Publication date
19 March 2026
Language
EN